• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用 HSP70 介导的蛋白质周转来破坏 N-Myc 的蛋白稳态可改善神经内分泌前列腺癌的治疗效果。

Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer.

机构信息

Department of Urologic Surgery, University of California, Davis, CA, USA.

Department of Urology, West China Hospital, Sichuan University, Sichuan, China.

出版信息

Nat Commun. 2024 Aug 5;15(1):6626. doi: 10.1038/s41467-024-50459-x.

DOI:10.1038/s41467-024-50459-x
PMID:39103353
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11300456/
Abstract

N-Myc is a key driver of neuroblastoma and neuroendocrine prostate cancer (NEPC). One potential way to circumvent the challenge of undruggable N-Myc is to target the protein homeostasis (proteostasis) system that maintains N-Myc levels. Here, we identify heat shock protein 70 (HSP70) as a top partner of N-Myc, which binds a conserved "SELILKR" motif and prevents the access of E3 ubiquitin ligase, STIP1 homology and U-box containing protein 1 (STUB1), possibly through steric hindrance. When HSP70's dwell time on N-Myc is increased by treatment with the HSP70 allosteric inhibitor, STUB1 is in close proximity with N-Myc and becomes functional to promote N-Myc ubiquitination on the K416 and K419 sites and forms polyubiquitination chains linked by the K11 and K63 sites. Notably, HSP70 inhibition significantly suppressed NEPC tumor growth, increased the efficacy of aurora kinase A (AURKA) inhibitors, and limited the expression of neuroendocrine-related pathways.

摘要

N-Myc 是神经母细胞瘤和神经内分泌前列腺癌(NEPC)的关键驱动因素。规避难以靶向的 N-Myc 这一挑战的一种潜在方法是针对维持 N-Myc 水平的蛋白质稳态(proteostasis)系统。在这里,我们确定热休克蛋白 70(HSP70)为 N-Myc 的顶级伴侣,它与保守的“SELILKR”基序结合,并通过空间位阻防止 E3 泛素连接酶、STIP1 同源和 U -box 含有蛋白 1(STUB1)的接近,可能通过空间位阻来防止接近。当 HSP70 的别构抑制剂增加 HSP70 在 N-Myc 上的停留时间时,STUB1 与 N-Myc 紧密接近并变得能够促进 N-Myc 在 K416 和 K419 位点上的泛素化,并形成通过 K11 和 K63 位点连接的多泛素化链。值得注意的是,HSP70 抑制显著抑制了 NEPC 肿瘤的生长,提高了极光激酶 A(AURKA)抑制剂的疗效,并限制了神经内分泌相关途径的表达。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a1/11300456/3e263a6d0d82/41467_2024_50459_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a1/11300456/4783752e2ad2/41467_2024_50459_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a1/11300456/af477397293d/41467_2024_50459_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a1/11300456/6328f351bea5/41467_2024_50459_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a1/11300456/72f97df8e500/41467_2024_50459_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a1/11300456/25e6e09ab5d8/41467_2024_50459_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a1/11300456/59973b721494/41467_2024_50459_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a1/11300456/c383a252e258/41467_2024_50459_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a1/11300456/3e263a6d0d82/41467_2024_50459_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a1/11300456/4783752e2ad2/41467_2024_50459_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a1/11300456/af477397293d/41467_2024_50459_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a1/11300456/6328f351bea5/41467_2024_50459_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a1/11300456/72f97df8e500/41467_2024_50459_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a1/11300456/25e6e09ab5d8/41467_2024_50459_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a1/11300456/59973b721494/41467_2024_50459_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a1/11300456/c383a252e258/41467_2024_50459_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a1/11300456/3e263a6d0d82/41467_2024_50459_Fig8_HTML.jpg

相似文献

1
Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer.利用 HSP70 介导的蛋白质周转来破坏 N-Myc 的蛋白稳态可改善神经内分泌前列腺癌的治疗效果。
Nat Commun. 2024 Aug 5;15(1):6626. doi: 10.1038/s41467-024-50459-x.
2
Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.针对神经内分泌前列腺癌中的 MYCN-PARP-DNA 损伤反应途径。
Clin Cancer Res. 2018 Feb 1;24(3):696-707. doi: 10.1158/1078-0432.CCR-17-1872. Epub 2017 Nov 14.
3
Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.激活的 ALK 通过 Wnt/β-连环蛋白信号与 N-Myc 合作诱导神经内分泌前列腺癌。
Cancer Res. 2021 Apr 15;81(8):2157-2170. doi: 10.1158/0008-5472.CAN-20-3351. Epub 2021 Feb 26.
4
MYCN Transforms Prostate Epithelium to Neuroendocrine Prostate Cancer.MYCN 转化前列腺上皮为神经内分泌前列腺癌。
Cancer Discov. 2016 Jun;6(6):OF19. doi: 10.1158/2159-8290.CD-RW2016-066. Epub 2016 Apr 14.
5
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.神经内分泌前列腺癌的分子特征分析与新药靶标的鉴定。
Cancer Discov. 2011 Nov;1(6):487-95. doi: 10.1158/2159-8290.CD-11-0130.
6
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.N-Myc诱导一种由EZH2介导的转录程序驱动神经内分泌前列腺癌。
Cancer Cell. 2016 Oct 10;30(4):563-577. doi: 10.1016/j.ccell.2016.09.005.
7
Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer.STUB1/HSP70 复合物的蛋白稳态控制对晚期前列腺癌中雄激素受体靶向治疗的敏感性。
Nat Commun. 2018 Nov 16;9(1):4700. doi: 10.1038/s41467-018-07178-x.
8
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.极光激酶 A 抑制剂alisertib 治疗去势抵抗性和神经内分泌前列腺癌的 II 期临床试验:疗效和生物标志物。
Clin Cancer Res. 2019 Jan 1;25(1):43-51. doi: 10.1158/1078-0432.CCR-18-1912. Epub 2018 Sep 19.
9
Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer.N-Myc 和 AURKA 的双重抑制剂作为神经内分泌前列腺癌的潜在治疗方法。
Int J Mol Sci. 2020 Nov 5;21(21):8277. doi: 10.3390/ijms21218277.
10
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.聚腺苷二磷酸核糖聚合酶抑制剂抑制去势抵抗性前列腺癌中的 GR-MYCN-CDK5-RB1-E2F1 信号传导和神经内分泌分化。
Clin Cancer Res. 2019 Nov 15;25(22):6839-6851. doi: 10.1158/1078-0432.CCR-19-0317. Epub 2019 Aug 22.

引用本文的文献

1
Heat Shock Protein Family A Member 1A Attenuates Apoptosis and Oxidative Stress via ERK/JNK Pathway in Hyperplastic Prostate.热休克蛋白家族A成员1A通过ERK/JNK通路减轻前列腺增生中的细胞凋亡和氧化应激。
MedComm (2020). 2025 Mar 10;6(3):e70129. doi: 10.1002/mco2.70129. eCollection 2025 Mar.
2
Emerging Therapeutic Targets of Neuroendocrine Prostate Cancer.神经内分泌前列腺癌的新兴治疗靶点
Curr Oncol Rep. 2025 Apr;27(4):362-374. doi: 10.1007/s11912-025-01643-9. Epub 2025 Feb 27.

本文引用的文献

1
Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution.前列腺癌中的谱系可塑性和治疗耐药性:遗传学、表观遗传学和进化的交集。
Front Endocrinol (Lausanne). 2023 Jun 30;14:1191311. doi: 10.3389/fendo.2023.1191311. eCollection 2023.
2
The E3 Ubiquitin Ligase, CHIP/STUB1, Inhibits Aggregation of Phosphorylated Proteoforms of Microtubule-associated Protein Tau (MAPT).E3 泛素连接酶 CHIP/STUB1 抑制微管相关蛋白 Tau(MAPT)磷酸化蛋白构象的聚集。
J Mol Biol. 2023 Jun 1;435(11):168026. doi: 10.1016/j.jmb.2023.168026. Epub 2023 Jun 16.
3
Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models.
别构抑制 HSP70 与 STUB1 协同作用增强恩扎卢胺在抗雄激素耐药前列腺肿瘤和患者来源模型中的疗效。
Pharmacol Res. 2023 Mar;189:106692. doi: 10.1016/j.phrs.2023.106692. Epub 2023 Feb 10.
4
HSP70-binding motifs function as protein quality control degrons.HSP70 结合基序作为蛋白质质量控制降解基序发挥作用。
Cell Mol Life Sci. 2023 Jan 7;80(1):32. doi: 10.1007/s00018-022-04679-3.
5
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.新型 AKR1C3 和雄激素受体轴抑制剂与恩扎卢胺联合治疗晚期前列腺癌。
Oncogene. 2023 Feb;42(9):693-707. doi: 10.1038/s41388-022-02566-6. Epub 2023 Jan 3.
6
Dynamic plasticity of prostate cancer intermediate cells during androgen receptor-targeted therapy.雄激素受体靶向治疗期间前列腺癌中间细胞的动态可塑性。
Cell Rep. 2022 Jul 26;40(4):111123. doi: 10.1016/j.celrep.2022.111123.
7
A campaign targeting a conserved Hsp70 binding site uncovers how subcellular localization is linked to distinct biological activities.靶向保守的 Hsp70 结合位点的研究揭示了亚细胞定位与不同生物学活性之间的关系。
Cell Chem Biol. 2022 Aug 18;29(8):1303-1316.e3. doi: 10.1016/j.chembiol.2022.06.006. Epub 2022 Jul 12.
8
Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer.转移性去势抵抗性前列腺癌内在表型分类的治疗意义。
Clin Cancer Res. 2022 Jul 15;28(14):3127-3140. doi: 10.1158/1078-0432.CCR-21-4289.
9
Systematic analysis of alterations in the ubiquitin proteolysis system reveals its contribution to driver mutations in cancer.对泛素蛋白水解系统改变的系统分析揭示了其对癌症驱动突变的作用。
Nat Cancer. 2020 Jan;1(1):122-135. doi: 10.1038/s43018-019-0001-2. Epub 2019 Dec 2.
10
Selective vulnerabilities in the proteostasis network of castration-resistant prostate cancer.雄激素剥夺治疗抵抗性前列腺癌中蛋白质稳态网络的选择性脆弱性。
Cell Chem Biol. 2022 Mar 17;29(3):490-501.e4. doi: 10.1016/j.chembiol.2022.01.008. Epub 2022 Feb 1.